Thus, the combination of an anti-IGF-IR antibody with mTOR inhibitors was shown to block the Akt-signaling pathway in rhabdomyosarcoma, breast, and prostate carcinomas, resulting in an additive increase in cell growth-inhibition [9,10]. Here, IGF1R is linked to rhabdomyosarcoma.